Pancreatic Cancer Research

ResearcherUniversity of KentuckyActive in the last 2 years

Reema Anil Patel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8650-6122; OpenAlex author ID A5045243780. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2022: 2 papers, 1 trial · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 7

  1. Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2026.1675133↗
  2. Transcriptomic Profiling and Demographic Analysis of Appalachian Patients with Pancreatic Ductal Adenocarcinoma using the Purity Independent Subtyping of Tumor… First author DOI 10.64898/2026.09.22.26363302↗
  3. Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16011-3↗
  4. Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.13023/jah.0601.02↗
  5. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348221117031↗
  6. Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0270832↗
  7. Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression. Co-author DOI 10.3390/cancers14133051↗

Trials 1

  1. GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care Principal investigator NCT05391126↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael J. Cavnar · 7 shared papers, 2022–2026 · strength 1.38
  2. Joseph Kim · 7 shared papers, 2022–2026 · strength 1.38
  3. Megan M. Harper · 4 shared papers, 2022–2024 · strength 0.70
  4. Hannah G. McDonald · 3 shared papers, 2024–2026 · strength 0.60
  5. Anna M. Reagan · 2 shared papers, 2024–2026 · strength 0.41
  6. Chelsey Mckenna Williams · 2 shared papers, 2024–2026 · strength 0.40
  7. Emily Cassim · 2 shared papers, 2024 · strength 0.36
  8. Erin E. Burke · 2 shared papers, 2024 · strength 0.36
  9. Mei Gao · 2 shared papers, 2022 · strength 0.34
  10. Deepak Vadehra · 1 shared paper, 2026 · strength 0.23
  11. Justin B. Miller · 1 shared paper, 2026 · strength 0.23
  12. Ashish Manne · 1 shared paper, 2026 · strength 0.23
  13. Carlos H.F. Chan · 1 shared paper, 2026 · strength 0.23
  14. Dae Won Kim · 1 shared paper, 2026 · strength 0.23
  15. Thomas Amburn · 1 shared paper, 2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.